X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New survey: Voters seriously concerned about fine print in reconciliation bill

By Mark Keida  |    August 12, 2022
With a final vote in Congress expected on a reconciliation spending bill, a new Morning Consult survey explores what this legislation actually does – and does not do – and finds that voters are...   Read More

Myth vs. Fact: The Senate’s latest price setting proposal

By Nicole Longo  |    August 5, 2022
The narratives being built around the Senate’s latest price setting proposal frame it as a bill intended to lower drug prices for patients and address rising inflation. But those narratives aren’t...   Read More

The Senate’s latest price setting proposal will undermine U.S. economic growth

By Nicole Longo  |    August 3, 2022
Last week, we examined ways the latest drug pricing proposal will undermine patient access to medicines, American medical innovation and our health care system as a whole. But there is another...   Read More

Celebrating Medicare’s 57th anniversary

By Gabby Migliara  |    August 2, 2022
In case you missed it, Saturday, July 30, marked the anniversary of Medicare. For 57 years, Medicare has helped pay for medical care for Americans over the age of 65, as well as younger Americans...   Read More

New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers

By Brian Newell  |    August 1, 2022
A new analysis by the health care analytics and research firm Avalere reveals the partisan drug pricing bill will have a much deeper impact on the biopharmaceutical research industry than previously...   Read More

The Senate’s latest price setting proposal will undermine: Our health care system

By Nicole Longo  |    July 28, 2022
Members of Congress continue to push a misguided drug pricing proposal under the guise of negotiation as part of the reconciliation package. This proposal is nothing short of government price setting...   Read More

The Senate’s latest price setting proposal will undermine: American medical innovation

By Nicole Longo  |    July 27, 2022
Members of Congress continue to push a misguided drug pricing proposal under the guise of negotiation as part of the reconciliation package. This proposal is nothing short of government price setting...   Read More

The Senate’s latest price setting proposal will undermine: Patient access to medicines

By Nicole Longo  |    July 26, 2022
Members of Congress continue to push a misguided drug pricing proposal under the guise of negotiation as part of the reconciliation package. This proposal is nothing short of government price setting...   Read More

The Patient Perspective: Government price-setting harms patients

By Andrew Powaleny  |    July 22, 2022
Unfortunately, policymakers are again looking for bumper-sticker answers to the health care affordability challenges many Americans face, ignoring real commonsense solutions in exchange for flawed...   Read More

Putting patients first at the state level — A conversation with Mark Reisenauer, President of Astellas Pharma US

By Scott LaGanga  |    July 14, 2022
Our industry continues working to improve patient access and affordability for medicines at the state level. I recently had the opportunity to connect with PhRMA board member Mark Reisenauer,...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates